Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Auner, Holger W ^a   Moody, Anne Marie ^a   Ward, Theresa H ^b   Kraus, Marianne ^c   Milan, Enrico ^d   May, Philippa ^a   Chaidos, Aristeidis ^a   Driessen, Christoph ^c   Cenci, Simone ^d   Dazzi, Francesco ^a   Rahemtulla, Amin ^a   Apperley, Jane F ^a   Karadimitris, Anastasios ^a   Dillon, Niall ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BORTEZOMIB; CELL PROTEIN; PROTEASOME; PROTEIN P97;

APOPTOSIS; ARTICLE; CONCEPTUAL FRAMEWORK; ELECTRON MICROSCOPY; ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MULTIPLE MYELOMA; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN TARGETING; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS;

ADENOSINE TRIPHOSPHATASES; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; ENDOPLASMIC RETICULUM; ENZYME INHIBITORS; HUMANS; MULTIPLE MYELOMA; NUCLEAR PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEIN BIOSYNTHESIS; PROTEOLYSIS; SIGNAL TRANSDUCTION;

EID: 84884268185     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074415     Document Type: Article

References (57)

1. Aronson LI, Davies FE, (2012) DangER: protein ovERload. Targeting protein degradation to treat myeloma. Haematologica 97: 1119-1130. doi:10.3324/haematol.2012.064923. PubMed: 22580998.
2. Schröder M, Kaufman RJ, (2005) The mammalian unfolded protein response. Annu Rev Biochem 74: 739-789. doi:10.1146/annurev.biochem.73.011303.074134. PubMed: 15952902.
3. Vembar SS, Brodsky JL, (2008) One step at a time: endoplasmic reticulum-associated degradation. Nat Rev Mol Cell Biol 9: 944-957. doi:10.1038/nrm2546. PubMed: 19002207.
4. Tabas I, Ron D, (2011) Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol 13: 184-190. doi:10.1038/ncb0311-184. PubMed: 21364565.
5. Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, et al. (2009) The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 113: 3040-3049. doi:10.1182/blood-2008-08-172734. PubMed: 19164601.
6. Cenci S, Mezghrani A, Cascio P, Bianchi G, Cerruti F, et al. (2006) Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J 25: 1104-1113. doi:10.1038/sj.emboj.7601009. PubMed: 16498407.
7. Auner HW, Beham-Schmid C, Dillon N, Sabbattini P, (2010) The life span of short-lived plasma cells is partly determined by a block on activation of apoptotic caspases acting in combination with endoplasmic reticulum stress. Blood 116: 3445-3455. doi:10.1182/blood-2009-10-250423. PubMed: 20651073.
8. Dimopoulos MA, San-Miguel JF, Anderson KC, (2011) Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Eur J Haematol 86: 1-15. doi:10.1111/j.1600-0609.2010.01542.x. PubMed: 20942854.
9. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr., Lee KP, et al. (2006) Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107: 4907-4916. doi:10.1182/blood-2005-08-3531. PubMed: 16507771.
10. Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH, (2003) Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A 100: 9946-9951. doi:10.1073/pnas.1334037100. PubMed: 12902539.
11. Wang Q, Mora-Jensen H, Weniger MA, Perez-Galan P, Wolford C, et al. (2009) ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci U S A 106: 2200-2205. doi:10.1073/pnas.0807611106. PubMed: 19164757.
12. Meister S, Schubert U, Neubert K, Herrmann K, Burger R, et al. (2007) Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 67: 1783-1792. doi:10.1158/0008-5472.CAN-06-2258. PubMed: 17308121.
13. Hoang B, Benavides A, Shi Y, Frost P, Lichtenstein A, (2009) Effect of autophagy on multiple myeloma cell viability. Mol Cancer Ther 8: 1974-1984. doi:10.1158/1535-7163.MCT-08-1177. PubMed: 19509276.
14. David E, Kaufman JL, Flowers CR, Schafer-Hales K, Torre C, et al. (2010) Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. Blood 116: 5285-5288. doi:10.1182/blood-2010-03-272393. PubMed: 20844234.
15. Rückrich T, Kraus M, Gogel J, Beck A, Ovaa H, et al. (2009) Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia 23: 1098-1105. doi:10.1038/leu.2009.8. PubMed: 19225532.
16. Nakatsukasa K, Brodsky JL, (2008) The recognition and retrotranslocation of misfolded proteins from the endoplasmic reticulum. Traffic 9: 861-870. doi:10.1111/j.1600-0854.2008.00729.x. PubMed: 18315532.
17. Ye Y, Meyer HH, Rapoport TA, (2003) Function of the p97-Ufd1-Npl4 complex in retrotranslocation from the ER to the cytosol: dual recognition of nonubiquitinated polypeptide segments and polyubiquitin chains. J Cell Biol 162: 71-84. doi:10.1083/jcb.200302169. PubMed: 12847084.
18. Ernst R, Mueller B, Ploegh HL, Schlieker C, (2009) The otubain YOD1 is a deubiquitinating enzyme that associates with p97 to facilitate protein dislocation from the ER. Mol Cell 36: 28-38. doi:10.1016/j.molcel.2009.09.016. PubMed: 19818707.
19. Wójcik C, Rowicka M, Kudlicki A, Nowis D, McConnell E, et al. (2006) Valosin-containing protein (p97) is a regulator of endoplasmic reticulum stress and of the degradation of N-end rule and ubiquitin-fusion degradation pathway substrates in mammalian cells. Mol Biol Cell 17: 4606-4618. doi:10.1091/mbc.E06-05-0432. PubMed: 16914519.
20. Ye Y, Meyer HH, Rapoport TA, (2001) The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol. Nature 414: 652-656. doi:10.1038/414652a. PubMed: 11740563.
21. Ye Y, Shibata Y, Kikkert M, van Voorden S, Wiertz E, et al. (2005) Recruitment of the p97 ATPase and ubiquitin ligases to the site of retrotranslocation at the endoplasmic reticulum membrane. Proc Natl Acad Sci U S A 102: 14132-14138. doi:10.1073/pnas.0505006102. PubMed: 16186510.
22. Meyer H, (2012) p97 complexes as signal integration hubs. BMC Biol 10: 48. doi:10.1186/1741-7007-10-48. PubMed: 22694940.
23. Uchiyama K, Totsukawa G, Puhka M, Kaneko Y, Jokitalo E, et al. (2006) p37 is a p97 adaptor required for Golgi and ER biogenesis in interphase and at the end of mitosis. Dev Cell 11: 803-816. doi:10.1016/j.devcel.2006.10.016. PubMed: 17141156.
24. Verma R, Oania R, Fang R, Smith GT, Deshaies RJ, (2011) Cdc48/p97 mediates UV-dependent turnover of RNA Pol II. Mol Cell 41: 82-92. doi:10.1016/j.molcel.2010.12.017. PubMed: 21211725.
25. Yamanaka K, Sasagawa Y, Ogura T, (2012) Recent advances in p97/VCP/Cdc48 cellular functions. Biochim Biophys Acta 1823: 130-137. doi:10.1016/j.bbamcr.2011.07.001. PubMed: 21781992.
26. Chou TF, Brown SJ, Minond D, Nordin BE, Li K, et al. (2011) Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proc Natl Acad Sci U S A 108: 4834-4839. doi:10.1073/pnas.1015312108. PubMed: 21383145.
27. Chou TF, Deshaies RJ, (2011) Development of p97 AAA ATPase inhibitors. Autophagy 7: 1091-1092. doi:10.4161/auto.7.9.16489. PubMed: 21606684.
28. Wang Q, Li L, Ye Y, (2008) Inhibition of p97-dependent protein degradation by Eeyarestatin I. J Biol Chem 283: 7445-7454. doi:10.1074/jbc.M708347200. PubMed: 18199748.
29. Wang Q, Shinkre BA, Lee JG, Weniger MA, Liu Y, et al. (2010) The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group. PLOS ONE 5: e15479. doi:10.1371/journal.pone.0015479. PubMed: 21124757.
30. Yi P, Higa A, Taouji S, Bexiga MG, Marza E, et al. (2012) Sorafenib-mediated targeting of the AAA(+) ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death. Mol Cancer Ther 11: 2610-2620. doi:10.1158/1535-7163.MCT-12-0516. PubMed: 23041544.
31. Kharaziha P, De Raeve H, Fristedt C, Li Q, Gruber A, et al. (2012) Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model. Cancer Res 72: 5348-5362. doi:10.1158/0008-5472.CAN-12-0658. PubMed: 22952216.
32. Fessart D, Marza E, Taouji S, Delom F, Chevet E, (2013) P97/CDC-48: Proteostasis control in tumor cell biology. Cancer Lett, 337: 26-34. PubMed: 23726843.
33. Vij N, (2008) AAA ATPase p97/VCP: cellular functions, disease and therapeutic potential. J Cell Mol Med 12: 2511-2518. doi:10.1111/j.1582-4934.2008.00462.x. PubMed: 18798739.
34. Ward TH, (2007) Trafficking through the early secretory pathway of mammalian cells. Methods Mol Biol 390: 281-296. doi:10.1007/978-1-59745-466-7_19. PubMed: 17951695.
35. Kirk SJ, Cliff JM, Thomas JA, Ward TH, (2010) Biogenesis of secretory organelles during B cell differentiation. J Leukoc Biol 87: 245-255. doi:10.1189/jlb.1208774. PubMed: 19889725.
36. Kraus M, Bader J, Overkleeft H, Driessen C, (2013) Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance. Blood. Cancer J 3: e103.
37. Mannava S, Zhuang D, Nair JR, Bansal R, Wawrzyniak JA, et al. (2012) KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. Blood 119: 1450-1458. doi:10.1182/blood-2011-04-346676. PubMed: 22144178.
38. Wang F, Song W, Brancati G, Segatori L, (2011) Inhibition of endoplasmic reticulum-associated degradation rescues native folding in loss of function protein misfolding diseases. J Biol Chem 286: 43454-43464. doi:10.1074/jbc.M111.274332. PubMed: 22006919.
39. Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, et al. (2012) Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol 30: 1949-1952. doi:10.1200/JCO.2011.36.5726. PubMed: 22547600.
40. Steinbrunn T, Stühmer T, Gattenlöhner S, Rosenwald A, Mottok A, et al. (2011) Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. Blood 117: 1998-2004. doi:10.1182/blood-2010-05-284422. PubMed: 21149634.
41. Parlati F, Lee SJ, Aujay M, Suzuki E, Levitsky K, et al. (2009) Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 114: 3439-3447. doi:10.1182/blood-2009-05-223677. PubMed: 19671918.
42. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, et al. (2005) Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65: 6282-6293. doi:10.1158/0008-5472.CAN-05-0676. PubMed: 16024630.
43. Bernales S, McDonald KL, Walter P, (2006) Autophagy counterbalances endoplasmic reticulum expansion during the unfolded protein response. PLOS Biol 4: e423. doi:10.1371/journal.pbio.0040423. PubMed: 17132049.
44. Sriburi R, Jackowski S, Mori K, Brewer JW, (2004) XBP1: a link between the unfolded protein response, lipid biosynthesis, and biogenesis of the endoplasmic reticulum. J Cell Biol 167: 35-41. doi:10.1083/jcb.200406136. PubMed: 15466483.
45. Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, et al. (2002) Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 17: 51-62. doi:10.1016/S1074-7613(02)00335-7. PubMed: 12150891.
46. Hyun T, Yam A, Pece S, Xie X, Zhang J, et al. (2000) Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood 96: 3560-3568. PubMed: 11071655.
47. Ron D, Walter P, (2007) Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8: 519-529. doi:10.1038/nrm2199. PubMed: 17565364.
48. Marissen WE, Guo Y, Thomas AA, Matts RL, Lloyd RE, (2000) Identification of caspase 3-mediated cleavage and functional alteration of eukaryotic initiation factor 2alpha in apoptosis. J Biol Chem 275: 9314-9323. doi:10.1074/jbc.275.13.9314. PubMed: 10734073.
49. Saelens X, Kalai M, Vandenabeele P, (2001) Translation inhibition in apoptosis: caspase-dependent PKR activation and eIF2-alpha phosphorylation. J Biol Chem 276: 41620-41628. doi:10.1074/jbc.M103674200. PubMed: 11555640.
50. Morley SJ, Coldwell MJ, Clemens MJ, (2005) Initiation factor modifications in the preapoptotic phase. Cell Death Differ 12: 571-584. doi:10.1038/sj.cdd.4401591. PubMed: 15900314.
51. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N, (2006) mTOR, translation initiation and cancer. Oncogene 25: 6416-6422. doi:10.1038/sj.onc.1209888. PubMed: 17041626.
52. Hideshima T, Chauhan D, Ishitsuka K, Yasui H, Raje N, et al. (2005) Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. Oncogene 24: 3121-3129. doi:10.1038/sj.onc.1208522. PubMed: 15735676.
53. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, et al. (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12: 431-440. doi:10.1016/S1470-2045(11)70081-X. PubMed: 21507715.
54. Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, et al. (2011) Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 17: 2734-2743. doi:10.1158/1078-0432.CCR-10-1950. PubMed: 21364033.
55. Valle CW, Min T, Bodas M, Mazur S, Begum S, et al. (2011) Critical role of VCP/p97 in the pathogenesis and progression of non-small cell lung carcinoma. PLOS ONE 6: e29073. doi:10.1371/journal.pone.0029073. PubMed: 22216170.
56. Boyault C, Gilquin B, Zhang Y, Rybin V, Garman E, et al. (2006) HDAC6-p97/VCP controlled polyubiquitin chain turnover. EMBO J 25: 3357-3366. doi:10.1038/sj.emboj.7601210. PubMed: 16810319.
57. Vij N, (2011) The case for therapeutic proteostasis modulators. Expert Opin Ther Targets 15: 233-236. doi:10.1517/14728222.2011.553610. PubMed: 21250874.